首页> 外文期刊>Vaccine >Protection in sheep against heterologous challenge with serotype Asia-1 foot-and-mouth disease virus using high potency vaccine
【24h】

Protection in sheep against heterologous challenge with serotype Asia-1 foot-and-mouth disease virus using high potency vaccine

机译:使用高效力疫苗,绵羊对异源挑战的保护,血清亚洲 - 1个患者病毒

获取原文
获取原文并翻译 | 示例
           

摘要

Foot-and-mouth disease virus (FMDV) serotype Asia-1 is prevalent in countries considered high risk for incursion into Australia, and has recently been responsible for a number of outbreaks in India, Bangladesh, Pakistan and Turkey. In vitro vaccine matching has shown a number of contemporary FMDV Asia-1 strains vary antigenically to the Asia-1 Shamir vaccine strain, which could result in poor protection with use of this vaccine. Therefore it was important to test the ability of the Asia-1 Shamir vaccine to protect sheep from challenge with a recent, heterologous strain at different days post-vaccination (dpv), including in an emergency vaccination scenario (challenge 4 or 7 dpv). Sheep (5 per group) were challenged with the Asia-1 /PAK/19/2014 isolate by intra-nasopharyngeal instillation 21 (V21), 7 (V7) or 4 (V4) dpv with high-potency (&6 PD50) Asia-1 Shamir vaccine. An additional five sheep were mock-vaccinated with adjuvant only (antigen-free preparation) 4 days prior to challenge (A4), and five unvaccinated (UV) control sheep were also challenged. All V21, V7 and V4 sheep were protected from clinical FMD. Eighty percent of V21 sheep and 40% of V7 sheep had sterile immunity, however all V4 sheep became systemically infected. Vaccination reduced excretion of virus in nasal and oral secretions but had no effect on the development of persistent infection. All A4 sheep and UV control sheep developed clinical FMD. The high-potency Asia-1 Shamir vaccine will protect against disease should an outbreak of contemporary Asia-1 viruses occur. Intranasopharyngeal instillation is an effective challenge method for use in vaccine efficacy studies in sheep. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
机译:口蹄疫病毒(FMDV)血清型亚洲 - 1在国家普遍认为入侵澳大利亚的高风险,并最近负责印度,孟加拉国,巴基斯坦和土耳其的爆发。体外疫苗匹配已经显示出许多当代FMDV亚洲-1菌株对亚洲-1疫苗疫苗菌株的抗原变化,这可能导致使用这种疫苗的保护差。因此,重要的是要测试亚洲-1 Shamir疫苗在疫苗接种后不同日(DPV)的初始异源菌株中保护绵羊免受攻击的能力,包括在紧急疫苗接种场景(挑战4或7dpv)中。绵羊(每组5个)对亚洲-1 / PAK / 19/2014的鼻咽滴注21(V21),7(V7)或4(V4)DPV具有高效(& 6 PD50)亚洲-1 Shamir疫苗。额外的五只羊在攻击前4天(A4),只有佐剂(抗原制剂),并且也挑战了五种未接种的(UV)对照绵羊。所有v21,v7和v4羊免受临床FMD的影响。百分之八十的V21羊和40%的v7绵羊具有无菌免疫力,但所有V4羊都变得全身感染。疫苗接种在鼻腔和口腔分泌物中降低病毒的排泄,但对持续感染的发展没有影响。所有A4绵羊和紫外线控制羊都开发了临床FMD。高效亚洲-1 Shamir疫苗将保护当代亚洲1病毒的爆发时会保护疾病。鼻咽滴注是一种有效的挑战方法,用于绵羊疫苗疗效研究。 Crown版权(c)2018由elestvier有限公司出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号